Loading…

Synthesis Anticonvulsant and Cytotoxic Evaluation of Benzimidazole-Quinoline Hybrids Schiff Base Analogs

Both, benzimidazole and quinoline pharmacophores have shown various activities against cancer, tuberculosis, malaria, fungal, viral, and bacterial infections. These moieties are considered highly potent nuclei in medicinal chemistry. Thus, this research work aims to produce a synergistic effect invo...

Full description

Saved in:
Bibliographic Details
Published in:Polycyclic aromatic compounds 2024-02, Vol.44 (2), p.960-980
Main Authors: Tiglani, Devleena, Mazumder, Avijit, Kumar, Rajnish, Yar, Mohammad Shahar, Ahsan, Mohamed Jawed, Shabana, Km
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Both, benzimidazole and quinoline pharmacophores have shown various activities against cancer, tuberculosis, malaria, fungal, viral, and bacterial infections. These moieties are considered highly potent nuclei in medicinal chemistry. Thus, this research work aims to produce a synergistic effect involving both nuclei in a single structure. A Series of literature work resulted in the synthesis of novel derivatives of 2-(1H-1,3-benzothiazole-2-yl)-N'-substituted quinoline-4-carbohydrazide 5a-q using a multiple-step reaction. Characterization of all compounds was successfully done using IR and 1 HNMR, 13 CNMR as well as elemental analysis. Furthermore, screening of all synthesized compounds has been shown a positive response as an anticonvulsant and antidepressant activity in mice. Compounds 5b, 5h, 5l, and 5n have shown potentially active on pentylenetetrazole-induced seizures in mice. The synthesized compounds were also screened on a panel of 60 cell lines by the National Cancer Institute according to standard screening protocol. Ten compounds were selected and evaluated via a single high dose (10 −5  M). In a one-dose assay, compounds 5j and 5o showed the highest activity on leukemia (CCRF-CEM) and renal cancer (A498) with growth inhibition (GI) of 70.91 and 61.15%.
ISSN:1040-6638
1563-5333
DOI:10.1080/10406638.2023.2183969